Retatrutide vs Semaglutide: What’s Different

Semaglutide is the GLP-1 medication most people have heard of, sold as Ozempic and Wegovy and now available as a once-daily pill too. It’s FDA approved and widely used. Retatrutide is a newer, investigational drug that isn’t available anywhere yet. The core difference is mechanism: semaglutide acts on one hormone receptor, while retatrutide acts on three, which helps explain retatrutide’s larger trial results. But semaglutide has something retatrutide doesn’t yet have, a proven, FDA-approved heart benefit. Here’s what’s different across the things that matter most.

The Quick Comparison

How They Work: One Receptor vs Three

Semaglutide is a single-receptor drug. It acts on the GLP-1 receptor, which slows how fast your stomach empties, helps you feel full sooner, and quiets the cravings and “food noise” that drive overeating. That one pathway has proven powerful, and our explainer on how semaglutide affects your hunger hormones breaks down the mechanism.

Retatrutide keeps the GLP-1 receptor and adds two more: GIP, which influences insulin response and fat handling, and glucagon, which appears to increase energy expenditure and fat burning. Put simply, semaglutide works mainly by reducing how much you eat, while retatrutide reduces intake and may also raise how much energy you burn. Those extra two levers are the leading explanation for retatrutide’s higher trial numbers.

Weight Loss Results: What the Trials Show

In the STEP 1 trial, adults on standard-dose Wegovy lost an average of about 15 percent of their body weight over 68 weeks. A newer, higher-dose version of Wegovy has since pushed that closer to 21 percent in testing, which narrows the gap with stronger medications. Our overview of Wegovy weight loss results covers what those numbers look like in practice. It’s worth noting that semaglutide was outperformed by tirzepatide in a head-to-head trial, so it isn’t the single strongest approved option, but it is one of the most studied and widely used.

Retatrutide’s trial numbers are higher: roughly 24 percent at 48 weeks in Phase 2, and about 28 percent at 68 weeks in Phase 3 topline results. Here’s the catch. Retatrutide and semaglutide have never been compared in the same trial, and these figures come from different studies with different participants and durations. The trend favors retatrutide on raw weight loss, but that’s a projection, not a proven head-to-head result.

Consider this scenario: someone sees 28 percent next to 15 percent and assumes retatrutide is nearly twice as effective. The reality is more measured, because trial-to-trial comparisons can mislead, and the higher-dose semaglutide options close much of that apparent gap.

Beyond Weight Loss: Semaglutide’s Proven Heart Benefit

This is where semaglutide pulls ahead today. Based on the SELECT trial, Wegovy is FDA approved to reduce the risk of major cardiovascular events like heart attack and stroke in adults who have established heart disease along with obesity or overweight. It’s the only obesity medication with that proven, approved benefit, and semaglutide has also gained an approval for a serious form of fatty liver disease. Our breakdown of the SELECT trial explains what that means for patients. Retatrutide is being studied for cardiovascular outcomes too, but those results aren’t in yet, so it can’t make the same claim.

Forms and Convenience: Injection or Pill

Semaglutide now comes in more than one format. Alongside the once-weekly injection, an oral version (a daily pill) became available for weight loss, which is a meaningful option for people who would rather not inject. Retatrutide, by contrast, is an injection only, and it’s available solely through clinical trials. For someone with needle anxiety, that flexibility is a real point in semaglutide’s favor.

Side Effects

The side-effect profiles overlap heavily. Both drugs most commonly cause gastrointestinal symptoms, nausea, vomiting, diarrhea, and constipation, which are dose-dependent and ease after each dose increase. Retatrutide adds a modest rise in heart rate and some reports of altered skin sensation at higher doses, both tied to its glucagon activity. Semaglutide’s safety profile has the advantage of years of real-world use across millions of patients, while retatrutide’s is still being mapped.

Availability and Cost

Semaglutide is approved, available by prescription as both an injection and a pill, and has established insurance and savings pathways. Retatrutide has no approval, no list price, and no legal pharmacy access. The “research-use-only” retatrutide sold online skips the quality and dosing oversight of real prescription medication, so it isn’t a safe or legal substitute. In practical terms, semaglutide is a choice you can make now, and retatrutide is one you can only watch for.

Which Should You Consider Now?

If retatrutide reaches the market with results like its trials, it could become a strong option down the road. Today, though, semaglutide is the one you can actually access, and it brings a proven track record, a pill-or-injection choice, and a unique heart benefit. If you’re deciding between the semaglutide options already available, our comparison of Ozempic vs Wegovy for weight loss is a helpful next read.

The clearest way to find your fit is a short assessment with a provider. You can compare your options with a provider to see what suits your health history, and keep retatrutide in view as its remaining trial results arrive.

This article is for educational purposes and is not medical advice. Retatrutide is an investigational medication that is not FDA approved and is not available by prescription. Consult a licensed healthcare provider before starting or changing any treatment. Individual results vary.